{
  "paper_id": "04bdb14ee4fde3edae739ffd6b0fc196aee7333e",
  "metadata": {
    "title": "TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib KEYWORDS-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/)",
    "coda_data_split": "train",
    "coda_paper_id": 7261,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.",
      "sentences": [
        [
          {
            "segment_text": "COVID-19 emerges as a pandemic disease with high mortality .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Development of effective prevention and treatment is an urgent need .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles .",
            "crowd_label": "finding"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "1",
    "sentence_num": "3",
    "segment_num": "3",
    "token_num": "48"
  }
}